click below
click below
Normal Size Small Size show me how
naplex
DM
| Question | Answer |
|---|---|
| metformin/sitagliptin | Janumet, Janumet XR |
| saxagliptin/dapagliflozin | Qtern |
| liraglutide/insulin degludec | Xultophy |
| lixisenatide/insulin glargin | Soliqua |
| glipizide | Preferred sulfonyluria in renal insufficiency, Contraindicated in sulfa allergy |
| glyburide | Can be used in pregnancy |
| Drug combination that severely increase risk of hypoglycemia | Insulin, sulfonylurea, and meglitinide |
| pioglitazone | Actos |
| pioglitazone contraindications | HF, NYHA III/IV |
| canagliflozin | Invokana |
| canagliflozin BBW | increased risk of amputations |
| SGLT2 eGFR contraindication | <30ml/min |
| empagliflozin | Jardiance |
| What SGLT2 inhibitor can cause hyperkalemia? | canagliflozin |
| What drug reduce CV events | metformin, empagliflozin, liraglutide |
| sitagliptin | Januvia |
| saxagliptin | Onglyza |
| linagliptin | Tradjenta, no renal dose adjustment |
| What risk increase use of saxagliptin and alogliptin? | HF |
| Major substrate of CYP3A4 and P-gp | saxagliptin, linagliptin |
| exenatide | Byetta |
| liraglutide | Victoza |
| dulaglutide | Trulicity |
| Albiglutide | Tanzeum |
| lixisenatide | Adlyxin |
| started total dose of insulin per day | 0.6u/kg/d |
| who is tested for diabetes | BMI >25 + 1 risk (AIC :5.7 etc.) |
| retinopathy screening | every 2 years |
| neuropathy screening | annually with 10g monofilament + another test |
| 1st line neuropathy agents | duloxetine and pregabalin |
| vaccinations | flu + pneumovax + at 65 prevnar + pneumovax in 1 year (at least 5 years from the previous dose) HepB (19-59 y.o.) |
| drugs that raise BG | systemic steroids b blockers loop and thiazide diuretics immunosuppressants (cyclosporin, tocrolimus) niacin PIs quinolones atypicl antipsych (clozapine, olanzapine, quetiapine) statins |
| Glucovance | metformin/glyburide |
| Xigduo | metformin/dapagliflozin |
| meglitinides meal relation | Should be taken 30 min before meals |
| pramlintide | Reduce insulin dose by 50% |
| Novolog, Novolog Flexipen | aspart, rapid-acting insulin |
| Apidra, Apidra Solostar | glulisine, rapid-acting insulin |
| Humalog, Humalog Kwikpen | lispro, rapid-acting insulin Humaloh Kwikpen comes in U-100 and U-200 |
| affreza is contraindicated | COPD, Asthma |
| Humulin R, Novolin R | regular insulin, short-acting regular insulin |
| Humulin R U-500, Novolin R Kwikpen | concentrated regular insulin |
| Humulin N Humulin N Kwikpen Novolin N | NPH, intermediate-acting insulin |
| Levemir, Levemir Flextouch | Detemir, long-acting insulin |
| Lantus Lantus Solostar Basaglar Kwikpen Toujeo Solostar (U-300) | Glargine, long-acting insulin |
| Tresiba Flextouch | degludec, long-acting insulin comes in U-200 |
| correction factor for 1 unit of rapid insulin | 1)1800/total daily units 2) BG - target BG/correction factor |
| correction factor for 1 unit of regular insulin | 1)1500/total daily units 2) BG - target BG/correction factor |
| converting NPH to Lantu | 80% NPH |
| Toujeo to Lantus | 80% toejeo |
| hypoglycemia | BG < 70 |
| Target BG for hospitalized patients | 140-180 |
| Drugs that can cause hypoglycemia | Linezolid lorcaserin (Belviq) Quinolones quinidine pentamidine propranolol octreatide |
| DKA | BG >250 PH <7.35 anion GAP >12 ketones in urine |
| Hyperglycemia hyperosmolar State (HHS) | BG >600 Extreme dehydration pH > 7.3, bicarbonate >15mEq/L |
| DKA tx | 1) Fluids: NS when BG 250 - D5W1/2NS 2) Regular insulin 1U/kg/hr 3) Monitor K 4) If ph <7 - treat with sodium bicarb |
| eGFR<30, do not use | metformin exenatide SGLT2 inhibitors |
| HF | TZDs alogliptin saxagliptin |
| G6PD deficiency | sulfanylurias |
| hepatotoxicity | alogliptin TZDs |
| ketoacidosis | SGLT2 |
| pancreatitis | GLP1 DPP4 |
| thyroid cancer | GLP1 |
| bladder cancer | TZDs |
| dehydration /hypotension | SGLT2 |